A new study points to $6.5B in public support building the scientific foundation of Gilead's remdesivir. Should that be reflected in the price?
By drug R&D standards, Gilead’s move to repurpose remdesivir for Covid-19 and grab an emergency use authorization was a remarkably easy, low-cost layup that required modest efficacy and a clean safety profile from just a small group of patients.
The drug OK also arrived after Gilead had paid much of the freight on getting it positioned to move fast.
In a study by Fred Ledley, director of the Center for Integration of Science and Industry at Bentley University in Waltham, MA, researchers concluded that the NIH had invested only $46.5 million in the research devoted to the drug ahead of the pandemic, a small sum compared to the more than $1 billion Gilead expected to spend getting it out this year, all on top of what it had already cost in R&D expenses.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.